Fig. 5From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabA 72-year-old female patient who received 12 ranibizumab injections in the year before baseline and 10 aflibercept injections in 1Â year of follow up. The patient had poor response to aflibercept with persistence of subretinal fluid noted at all follow-up visits. a Baseline, b Month 1, c Month 3, d Month 6, e Month 12Back to article page